Cerus Co. (CERS) Receives Consensus Recommendation of “Hold” from Brokerages

Cerus Co. (NASDAQ:CERS) has earned a consensus rating of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $6.50.

A number of equities analysts recently issued reports on the company. BTIG Research reissued a “hold” rating on shares of Cerus in a report on Thursday, January 25th. Zacks Investment Research lowered Cerus from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Cantor Fitzgerald reissued a “buy” rating and issued a $5.00 price objective on shares of Cerus in a report on Tuesday, January 23rd. Robert W. Baird reissued a “buy” rating and issued a $5.00 price objective on shares of Cerus in a report on Friday, December 1st. Finally, BidaskClub raised Cerus from a “strong sell” rating to a “sell” rating in a report on Friday, January 5th.

Shares of Cerus (CERS) traded down $0.08 during mid-day trading on Tuesday, reaching $3.85. The company had a trading volume of 744,600 shares, compared to its average volume of 1,906,219. Cerus has a 1-year low of $1.93 and a 1-year high of $5.43. The company has a market cap of $488.95, a price-to-earnings ratio of -6.53 and a beta of 2.22. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CERS. Teachers Advisors LLC lifted its position in Cerus by 9.7% in the second quarter. Teachers Advisors LLC now owns 260,081 shares of the biotechnology company’s stock worth $653,000 after purchasing an additional 22,896 shares during the period. UBS Asset Management Americas Inc. lifted its position in Cerus by 59.3% in the second quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 18,000 shares during the period. Northern Trust Corp lifted its position in Cerus by 3.2% in the second quarter. Northern Trust Corp now owns 1,269,773 shares of the biotechnology company’s stock worth $3,186,000 after purchasing an additional 39,684 shares during the period. Vanguard Group Inc. lifted its position in Cerus by 3.9% in the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock worth $12,281,000 after purchasing an additional 184,076 shares during the period. Finally, Ark Investment Management LLC lifted its position in Cerus by 126.5% in the second quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock worth $4,219,000 after purchasing an additional 938,647 shares during the period. Hedge funds and other institutional investors own 51.52% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Cerus Co. (CERS) Receives Consensus Recommendation of “Hold” from Brokerages” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3195435/cerus-co-cers-receives-consensus-recommendation-of-hold-from-brokerages.html.

Cerus Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.